FDA grants orphan drug status to Provectus' PV-10 for liver cancer treatment

[News]

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has received orphan drug designation by the U.S. Food and Drug Administration for Rose Bengal, the active ingredient in its novel oncology drug PV-10, for the treatment of hepatocellular carcinoma, the most common form of primary liver cancer.

More... (http://www.news-medical.net/news/20110427/FDA-grants-orphan-drug-status-to-Provectus-PV-10-for-liver-cancer-treatment.aspx)